Duke Center for Atrial Fibrillation, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Heart and Vascular Center, MetroHealth Medical Center, Cleveland, Ohio.
JAMA Cardiol. 2017 Mar 1;2(3):319-323. doi: 10.1001/jamacardio.2016.4936.
The joint American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) guidelines on the management of atrial fibrillation (AF) are used extensively to guide patient care.
To describe the evidence base and changes over time in the AHA/ACC/HRS guidelines on AF with respect to the distribution of recommendations across classes of recommendations and levels of evidence.
Data from the AHA/ACC/HRS guidelines on AF from 2001, 2006, 2011, and 2014 were abstracted. A total of 437 recommendations were included.
The number of recommendations and distribution of classes of recommendation (I, II, and III) and levels of evidence (A, B, and C) were determined for each guideline edition. Changes in recommendation class and level of evidence were analyzed using the 2001 and 2014 guidelines.
From 2001 to 2014, the total number of AF recommendations increased from 95 to 113. Numerically, there was a nonsignificant increase in the use of level of evidence B (30.5% to 39.8%; P = .17) and a nonsignificant decrease in the use of level of evidence C (60.0% to 51.3%; P = .21), with limited changes in the use of level A evidence (8.4% to 8.8%; P = .92). In the 2014 guideline document, 10 of 113 (8.8%) recommendations were supported by level of evidence A, whereas 58 of 113 (51.3%) were supported by level of evidence C. Most recommendations were equally split among class I (49/113; 43.4%) and class IIa/IIb (49/113; 43.4%), with the minority (15/113; 13.3%) assigned as class III. Most class I recommendations were supported by level of evidence C (29/49; 59.2%), whereas only 6 of 49 (12.2%) were supported by level of evidence A. No rate control category recommendations were supported by level of evidence A.
Some aspects of the quality of evidence underlying AHA/ACC/HRS AF guidelines have improved over time. However, the use of level of evidence A remains low and has not increased since 2001. These findings highlight the need for focused and pragmatic randomized studies on the clinical management of AF.
美国心脏病学会(ACC)、美国心脏协会(AHA)和心律学会(HRS)联合制定的心房颤动(AF)管理指南被广泛用于指导患者治疗。
描述 AHA/ACC/HRS 关于 AF 指南中的证据基础和随时间变化,涉及推荐类别在推荐级别和证据水平上的分布。
从 2001 年、2006 年、2011 年和 2014 年 AHA/ACC/HRS 关于 AF 的指南中提取数据。共纳入 437 项建议。
为每个指南版本确定了建议的数量和推荐类别(I、II 和 III)以及证据水平(A、B 和 C)的分布。使用 2001 年和 2014 年的指南分析了推荐类别和证据水平的变化。
从 2001 年到 2014 年,AF 建议总数从 95 项增加到 113 项。从数量上看,证据水平 B 的使用略有增加(30.5%至 39.8%;P=0.17),证据水平 C 的使用略有减少(60.0%至 51.3%;P=0.21),而证据水平 A 的使用变化不大(8.4%至 8.8%;P=0.92)。在 2014 年的指南文件中,113 项建议中有 10 项(8.8%)得到了证据水平 A 的支持,而 113 项中有 58 项(51.3%)得到了证据水平 C 的支持。大多数建议在 I 类(49/113;43.4%)和 IIa/IIb 类(49/113;43.4%)中平分秋色,而少数(15/113;13.3%)被归类为 III 类。大多数 I 类建议得到了证据水平 C 的支持(29/49;59.2%),而只有 6 项(49 项中的 12.2%)得到了证据水平 A 的支持。没有心率控制类别建议得到证据水平 A 的支持。
AHA/ACC/HRS AF 指南中证据基础的某些方面随着时间的推移有所改善。然而,自 2001 年以来,证据水平 A 的使用仍然很低,并没有增加。这些发现强调了需要针对 AF 的临床管理进行有针对性和务实的随机研究。